Literature DB >> 20140679

Serum profiles of monocyte chemoattractant protein-1 as a biomarker for patients recovering from myocardial infarction.

Katarzyna Korybalska1, Małgorzata Pyda, Stefan Grajek, Magdalena Lanocha, Andrzej Breborowicz, Janusz Witowski.   

Abstract

BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) plays a key role in the pathogenesis of atherosclerosis and has been proposed as a biomarker for patients with cardiovascular disease.
METHODS: To assess its clinical usefulness, serum MCP-1 concentrations were measured in patients with ST-elevation myocardial infarction (MI) at admission, immediately after percutaneous coronary intervention (PCI), at 24 h, and after 6 months.
RESULTS: We found no differences in MCP-1 concentrations between patients with acute MI, patients with stable coronary artery disease and healthy individuals. Although median MCP-1 concentrations in patients with MI were similar at admission and after 6 months, there were significant differences between individuals in how MCP-1 levels changed with time. As demonstrated by comparing baseline quartiles of MCP-1, the levels of MCP-1 tended to increase in patients with low MCP-1 concentration at admission, and decrease in patients with initially high MCP-1 levels. We found an inverse correlation between MCP-1 concentration at baseline and the time to reperfusion, and detected a significant decrease in MCP-1 concentration immediately after PCI. We also observed lower MCP-1 concentrations over time in patients who developed restenosis within 6 months. However, we did not confirm the association between MCP-1 concentrations at baseline and a number of previously implicated demographic, clinical and laboratory criteria.
CONCLUSIONS: Our data demonstrate some new aspects of MCP-1 measurement in patients with MI, but do not corroborate many earlier observations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20140679     DOI: 10.1007/s00392-010-0122-1

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  50 in total

1.  Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty.

Authors:  F Cipollone; M Marini; M Fazia; B Pini; A Iezzi; M Reale; L Paloscia; G Materazzo; E D'Annunzio; P Conti; F Chiarelli; F Cuccurullo; A Mezzetti
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-03       Impact factor: 8.311

2.  Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction.

Authors:  Hajime Morimoto; Masafumi Takahashi; Atsushi Izawa; Hirohiko Ise; Minoru Hongo; Pappachan E Kolattukudy; Uichi Ikeda
Journal:  Circ Res       Date:  2006-09-21       Impact factor: 17.367

3.  Effect of heparin on blood vascular endothelial growth factor levels in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Małgorzata Pyda; Katarzyna Korybalska; Krzysztof Ksiazek; Stefan Grajek; Magdalena Lanocha; Maciej Lesiak; Justyna Wiśniewska-Elnur; Anna Olasińska; Andrzej Breborowicz; Andrzej Cieśliński; Janusz Witowski
Journal:  Am J Cardiol       Date:  2006-08-07       Impact factor: 2.778

4.  Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study.

Authors:  Ron C Hoogeveen; Alanna Morrison; Eric Boerwinkle; J Shawn Miles; Charles E Rhodes; A Richey Sharrett; Christie M Ballantyne
Journal:  Atherosclerosis       Date:  2005-04-14       Impact factor: 5.162

5.  The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells.

Authors:  Shigeru Morikawa; Wakako Takabe; Chikage Mataki; Toru Kanke; Takahiro Itoh; Youichiro Wada; Akashi Izumi; Yasushi Saito; Takao Hamakubo; Tatsuhiko Kodama
Journal:  J Atheroscler Thromb       Date:  2002       Impact factor: 4.928

6.  Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.

Authors:  James A de Lemos; David A Morrow; Michael A Blazing; Petr Jarolim; Stephen D Wiviott; Marc S Sabatine; Robert M Califf; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2007-11-13       Impact factor: 24.094

7.  The prognostic value of monocyte chemoattractant protein-1/CCL2 in acute coronary syndromes.

Authors:  Nikolaos G Frangogiannis
Journal:  J Am Coll Cardiol       Date:  2007-11-13       Impact factor: 24.094

8.  Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome.

Authors:  Zhu-mei Xu; Shui-ping Zhao; Quan-zhong Li; Sai Nie; Hong-nian Zhou
Journal:  Clin Chim Acta       Date:  2003-12       Impact factor: 3.786

9.  Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium.

Authors:  Anders Gabrielsen; Patrick R Lawler; Wang Yongzhong; Daniel Steinbrüchel; Dimo Blagoja; Gabrielle Paulsson-Berne; Jens Kastrup; Göran K Hansson
Journal:  J Mol Cell Cardiol       Date:  2007-01-08       Impact factor: 5.000

Review 10.  Chemokines and cardiac fibrosis.

Authors:  Marcin Dobaczewski; Nikolaos Georgios Frangogiannis
Journal:  Front Biosci (Schol Ed)       Date:  2009-06-01
View more
  1 in total

1.  TNF-α, myocardial perfusion and function in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention.

Authors:  Eva S Kehmeier; Wolfgang Lepper; Martina Kropp; Christian Heiss; Ulrike Hendgen-Cotta; Jan Balzer; Mirja Neizel; Christian Meyer; Marc W Merx; Pablo E Verde; Christian Ohmann; Gerd Heusch; Malte Kelm; Tienush Rassaf
Journal:  Clin Res Cardiol       Date:  2012-05-06       Impact factor: 5.460

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.